Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials

Publisher Name :
Date: 01-Oct-2016
No. of pages: 457

"Delivery of this report will take 1-3 days after purchase."

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2010, including financial terms where available, including over 600 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Infectious Vaccines dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Infectious Vaccines dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Infectious Vaccines deals since 2010. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a review of the leading Infectious Vaccines deals since 2010. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Infectious Vaccines dealmaking with a brief summary followed by a comprehensive listing of Infectious Vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Infectious Vaccines technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

Report scope

Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials includes:

Trends in infectious vaccines dealmaking in the biopharma industry since 2010

Analysis of infectious vaccines deal structure

Access to headline, upfront, milestone and royalty data

Access to over 600 infectious vaccines deal records

Identify the most active infectious vaccine dealmakers since 2010

The leading infectious vaccines deals by value since 2010

Includes adjuvant deals and alliances since 2010

In Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific infectious therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 500 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Infectious Vaccines Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of infectious vaccines deal trends since 2010

Access infectious vaccines deal headline, upfront, milestone and royalty data

Analysis of the structure of infectious vaccines agreements with numerous real life case studies

Comprehensive access to over 600 links to actual infectious vaccines deals entered into by the world's biopharma companies, together with real world clause examples

Identify leading infectious vaccines deals by value since 2010

Identify the most active infectious vaccines dealmakers since 2010

Insight into the terms included in infectious vaccines agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Vaccines dealmaking
2.1. Introduction
2.2. Infectious Vaccines partnering over the years
2.3. Most active Infectious Vaccines dealmakers
2.4. Infectious Vaccines partnering by deal type
2.5. Infectious Vaccines partnering by therapy area
2.6. Deal terms for Infectious Vaccines partnering
2.6.1 Infectious Vaccines partnering headline values
2.6.2 Infectious Vaccines deal upfront payments
2.6.3 Infectious Vaccines deal milestone payments
2.6.4 Infectious Vaccines royalty rates

Chapter 3 - Leading Infectious Vaccines deals
3.1. Introduction
3.2. Top Infectious Vaccines deals by value

Chapter 4 - Most active Infectious Vaccines dealmakers
4.1. Introduction
4.2. Most active Infectious Vaccines dealmakers
4.3. Most active Infectious Vaccines partnering company profiles

Chapter 5 - Infectious Vaccines contracts dealmaking directory
5.1. Introduction
5.2. Infectious Vaccines contracts dealmaking directory

Chapter 6 - Infectious Vaccines dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Infectious Vaccines deals by company A-Z
Appendix 2 - Infectious Vaccines deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - Infectious Vaccines deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Appendix 4 - Infectious Vaccines deals by therapy area
Appendix 5 - Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Figures

Figure 1: Infectious Vaccines partnering since 2010
Figure 2: Active Infectious Vaccines dealmaking activity- 2010 to 2016
Figure 3: Infectious Vaccines partnering by deal type since 2010
Figure 4: Infectious Vaccines partnering by disease type since 2010
Figure 5: Infectious Vaccines deals with a headline value
Figure 6: Infectious Vaccines deals with an upfront value
Figure 7: Infectious Vaccines deals with a milestone value
Figure 8: Infectious Vaccines deals with a royalty rate value
Figure 9: Top Infectious Vaccines deals by value since 2010
Figure 10: Most active Infectious Vaccines dealmakers 2010 to 2016
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 [...]
  • Growing Demand in Emergent Markets To Boost Bakery Ingredients Market
    The baking ingredients market is predictable to grow at a CAGR of 5.2% from 2015 to reach an estimated value of US$ 15.19 billion by 2020. Evolving economies throughout the globe have been displaying demand for bakery ingredients at a greater rate in agreement with the economic growth. Numerous companies have been occupied on refining [...]
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • North America Drugs for Schistosomiasis Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 20-Feb-2017        Price: US 4480 Onwards        Pages: 120
    Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty. Scope of the Report: ......
  • Global Drugs for Schistosomiasis Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 20-Feb-2017        Price: US 3480 Onwards        Pages: 120
    Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty. Scope of the Report: This re......
  • Global Prostacyclin Market Research Report 2017
    Published: 14-Feb-2017        Price: US 2900 Onwards        Pages: 103
    Notes: Production, means the output of Prostacyclin Revenue, means the sales value of Prostacyclin This report studies Prostacyclin in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering - Actelion Pharmaceuticals - United Therapeutics Corporation - Gilead - Bayer ......
  • Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2017
    Published: 13-Feb-2017        Price: US 2250 Onwards        Pages: 149
    DelveInsight's, "Immune Checkpoints Activators- Competitive Landscape, Technology and Pipeline Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Immune Checkpoints Activators. This report provides information on the therapeutic development based on Immune Checkpoints Activators mechanism of action dealing w......
  • Global Calcitriol (CAS 32222-06-3) Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 11-Feb-2017        Price: US 3480 Onwards        Pages: 116
    Calcitriol is a white, crystalline compound which occurs naturally in humans. It has a calculated molecular weight of 416.65 and is soluble in organic solvents but relatively insoluble in water. Calcitriol is a synthetic vitamin D analog which is active in the regulation of the absorption of calcium from the gastrointestinal tract and its utilization in the body. The report focus on the Calcitriol formulations market survey. Scope of the Report: This report focuses on the C......
  • Europe Calcitriol (CAS 32222-06-3) Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 11-Feb-2017        Price: US 4480 Onwards        Pages: 116
    Calcitriol is a white, crystalline compound which occurs naturally in humans. It has a calculated molecular weight of 416.65 and is soluble in organic solvents but relatively insoluble in water. Calcitriol is a synthetic vitamin D analog which is active in the regulation of the absorption of calcium from the gastrointestinal tract and its utilization in the body. The report focus on the Calcitriol formulations market survey. Scope of the Report: This report focuses on the C......
  • EMEA Inhalation & Nasal Spray Generic Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2022
    Published: 09-Feb-2017        Price: US 4480 Onwards        Pages: 121
    "Generic drugs are drugs that are not associated with any company or a brand name and are subject to regulation of countries where they are dispensed. According to US FDA, A generic drug is identical--or bioequivalent--to a brand name drug in dosage form, safety, strength, route of administration, quality, performance characteristics and intended use. Inhalation & Nasal Spray is a kind of drug used to relieve sneezing, runny, stuffy, or itchy nose and itchy, watery eyes caused by ......
  • Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Paracetamol Market 2017 Forecast to 2022
    Published: 09-Feb-2017        Price: US 4880 Onwards        Pages: 116
    "Paracetamol, also named acetaminophen, is an active ingredient in hundreds of over-the-counter (OTC) and prescription medicines. It relieves pain and fever. And, it is also combined with other active ingredients in medicines that treat allergy, cough, colds, flu, and sleeplessness. In prescription medicines, acetaminophen is found with other active ingredients to treat moderate to severe pain. Acetaminophen can cause serious liver damage if more than directed is used. "......
  • Asia-Pacific Inhalation & Nasal Spray Generic Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2022
    Published: 08-Feb-2017        Price: US 4480 Onwards        Pages: 121
    "Generic drugs are drugs that are not associated with any company or a brand name and are subject to regulation of countries where they are dispensed. According to US FDA, A generic drug is identical--or bioequivalent--to a brand name drug in dosage form, safety, strength, route of administration, quality, performance characteristics and intended use. Inhalation & Nasal Spray is a kind of drug used to relieve sneezing, runny, stuffy, or itchy nose and itchy, watery eyes caused by ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs